Drugs / AQ-13
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00455494 | Jan 2005 → Dec 2006 | malaria | Tulane University Health Sciences Center | Completed | No outcome recorded |
| Phase 1 | NCT00323375 | Aug 1999 → Jun 2005 | malaria | Tulane University Health Sciences Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01614964 | Aug 2013 → Jan 2016 | Plasmodium falciparum malaria | Tulane University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AQ-13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01614964 ↗ |
| Modality | Small molecule | “investigational aminoquinoline antimalarial (AQ-13)” NCT00323375 ↗ |
| Route | Oral | “administered orally” NCT00323375 ↗ |